What are VEGF inhibitor drugs?

VEGF inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting VEGF (Vascular Endothelial Growth Factor)). 1 are currently marketed, with 8 more in clinical development.

What are the marketed VEGF inhibitor drugs?

Marketed VEGF inhibitor drugs include intravitreal Anti-VEGF injection.

VEGF inhibitor

1 marketed 6 in Phase 3 1 in Phase 2 1 in Phase 1

This page covers all VEGF inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF (Vascular Endothelial Growth Factor), VEGF-A, VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors.

Targets

VEGF (Vascular Endothelial Growth Factor) · VEGF-A · VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors · VEGFR2 · VEGF receptor · VEGF-A, VEGF-B, PlGF · VEGFR

Marketed (1)

intravitreal Anti-VEGF injection · Seoul National University Bundang Hospital · Ophthalmology
Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye.

Phase 3 pipeline (6)

miFL + bevacizumab · Pfizer · Oncology
miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor.
Anti-VEGF Therapy · Hoffmann-La Roche · Oncology, Ophthalmology
Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases.
Ramucirumab DP (IMC-1121B) · Eli Lilly and Company · Oncology
Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
rhuFab V2 (ranibizumab) · Genentech, Inc. · Ophthalmology
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A).
HR17031 injection · Jiangsu HengRui Medicine Co., Ltd. · Oncology
HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.
Placebo to bevacizumab · Hoffmann-La Roche · Oncology
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.

Phase 2 pipeline (1)

Aflibercept intravitreal injection · Innostellar Biotherapeutics Co.,Ltd · Ophthalmology
Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability.

Phase 1 pipeline (1)

AAV2-sFLT01 · Genzyme, a Sanofi Company · Oncology
VEGF inhibitor